Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055333 | 0.86 | WNT1 (0.33) | — | |
| SCHEMBL23055609 | 0.82 | KMO (0.38) | NR1I2KCNH2GRM2KMONPC1 | |
| Hydrochloric Acid SCHEMBL28926978 | 0.81 | GRM2 (0.37) | NR1I2KCNH2GRM2KMONPC1 | |
| SCHEMBL23045225 | 0.79 | GRIN2B (0.42) | — | |
| SCHEMBL24783025 | 0.77 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23055590 | 0.75 | KMO (0.50) | NR1I2KCNH2GRM2KMONPC1 | |
| Hydrochloric Acid SCHEMBL29974683 | 0.74 | KMO (0.49) | NR1I2KCNH2GRM2KMONPC1 | |
| Hydrochloric Acid SCHEMBL28926965 | 0.74 | KMO (0.49) | NR1I2KCNH2GRM2KMONPC1 | |
| SCHEMBL23055224 | 0.72 | MAPK8 (0.42) | KMONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23697920 | 0.70 | NR1I2 (0.34) | NR1I2KCNH2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | NR1I2 2733/4885KCNH2 143/4885GRM2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.